Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents

被引：12

作者：

Mizuno, Shohei ^{[1
]}

Kawamura, Koji ^{[2
]}

Hanamura, Ichiro ^{[1
]}

Sunami, Kazutaka ^{[3
]}

Mori, Takehiko ^{[4
]}

Nakamura, Fumihiko ^{[5
]}

Iida, Shinsuke ^{[6
]}

Nakazawa, Hideyuki ^{[7
]}

Makita, Masanori ^{[3
]}

Kako, Shinichi ^{[2
]}

Sawa, Masashi ^{[8
]}

Ueda, Yasunori ^{[9
,10
]}

Takahashil, Hiroyuki ^{[11
]}

Kanda, Yoshinobu ^{[2
]}

Ichinohe, Tatsuo ^{[12
]}

Atsuta, Yoshiko ^{[13
,14
]}

Takamatsu, Hiroyuki ^{[15
]}

Takami, Akiyoshi ^{[1
]}

机构：

[1] Aichi Med Univ, Dept Internal Med, Div Hematol, Nagakute, Aichi, Japan

[2] Jichi Med Univ, Saitama Med Ctr, Div Hematol, Saitama, Japan

[3] Natl Hosp Org Okayama Med Ctr, Dept Hematol, Okayama, Japan

[4] Keio Univ, Dept Med, Div Hematol, Sch Med, Tokyo, Japan

[5] Natl Ctr Global Hlth & Med, Div Hematol, Tokyo, Japan

[6] Nagoya City Univ Hosp, Dept Hematol & Oncol, Nagoya, Aichi, Japan

[7] Shinshu Univ, Dept Internal Med, Div Hematol, Sch Med, Matsumoto, Nagano, Japan

[8] Anjo Kosei Hosp, Dept Hematol & Oncol, Anjo, Aichi, Japan

[9] Kurashiki Cent Hosp, Dept Hematol Oncol, Kurashiki, Okayama, Japan

[10] Kurashiki Cent Hosp, Transfus & Hemapheresis Ctr, Kurashiki, Okayama, Japan

[11] Yokohama City Univ Med, Dept Hematol & Clin Immunol, Yokohama, Kanagawa, Japan

[12] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Hematol & Oncol, Hiroshima, Japan

[13] Japanese Data Ctr Hematopoiet Cell Transplantat, Nagoya, Aichi, Japan

[14] Nagoya Univ, Dept Healthcare Adm, Grad Sch Med, Nagoya, Aichi, Japan

[15] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Hematol Resp Med, Fac Med, Kanazawa, Ishikawa, Japan

来源：

BONE MARROW TRANSPLANTATION | 2019年 / 54卷 / 10期

关键词：

HIGH-DOSE CHEMOTHERAPY; ELDERLY-PATIENTS; SURVIVAL; DEXAMETHASONE; LENALIDOMIDE; OUTCOMES; THERAPY; TRENDS; MAINTENANCE; DARATUMUMAB;

D O I：

10.1038/s41409-019-0478-4

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Clinical trials evaluating the role of autologous hematopoietic stem cell transplantation (auto-HCT) in multiple myeloma have mostly included patients aged <65 years. Therefore, this study was aimed to evaluate the efficacy and safety of auto-HCT in elderly patients with multiple myeloma in the era of novel agents. We retrospectively analyzed 2056 patients with multiple myeloma, who underwent auto-HCT in 2007-2014 (287 were aged >= 65 years). We evaluated the 100-day treatment-related mortality (TRM) and overall survival (OS) in two groups; elderly patients (>= 65 years) who underwent auto-HCT compared with younger patients (<65 years). In the propensity score-matched-pair analysis used to adjust for possible selection bias, the incidence of 100-day TRM between patients aged <65 (0.4%; 95% confidence interval [CI]: 0.0-2.0%) and >= 65 years (1.2%; 95% CI: 0.3-3.1%) showed no statistically significant difference (p = 0.31). The probability of the 5-year OS after transplantation in those aged <65 (62.5%; 95% CI: 58.6-66.1%) and >= 65 (63.5%; 95% CI: 52.2-72.7%) years was also not significantly different (p = 0.56). This study showed that the safety and efficacy of autoHCT in elderly patients with multiple myeloma in the era of novel agents compared with younger patients were similar.

引用

页码：1595 / 1604

页数：10

共 33 条

[1] Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system [J].

Atsuta, Yoshiko ;

Suzuki, Ritsuro ;

Yoshimi, Ayami ;

Gondo, Hisashi ;

Tanaka, Junji ;

Hiraoka, Akira ;

Kato, Koji ;

Tabuchi, Ken ;

Tsuchida, Masahiro ;

Morishima, Yasuo ;

Mitamura, Makoto ;

Kawa, Keisei ;

Kato, Shunichi ;

Nagamura, Tokiko ;

Takanashi, Minoko ;

Kodera, Yoshihisa .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 86 (03) :269-274

[2] Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data) [J].

Atsuta, Yoshiko .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (01) :3-10

[3] Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma [J].

Attal, Michel ;

Lauwers-Cances, Valerie ;

Hulin, Cyrille ;

Leleu, Xavier ;

Caillot, Denis ;

Escoffre, Martine ;

Arnulf, Bertrand ;

Macro, Margaret ;

Belhadj, Karim ;

Garderet, Laurent ;

Roussel, Murielle ;

Payen, Catherine ;

Mathiot, Claire ;

Fermand, Jean P. ;

Meuleman, Nathalie ;

Rollet, Sandrine ;

Maglio, Michelle E. ;

Zeytoonjian, Andrea A. ;

Weller, Edie A. ;

Munshi, Nikhil ;

Anderson, Kenneth C. ;

Richardson, Paul G. ;

Facon, Thierry ;

Avet-Loiseau, Herve ;

Harousseau, Jean-Luc ;

Moreau, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) :1311-1320

[4] Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years [J].

Auner, H. W. ;

Szydlo, R. ;

Hoek, J. ;

Goldschmidt, H. ;

Stoppa, A. M. ;

Morgan, G. J. ;

Moreau, P. ;

Attal, M. ;

Marit, G. ;

Russell, N. ;

Brune, M. ;

Cook, G. ;

Sonneveld, P. ;

Schonland, S. ;

Garderet, L. ;

Kroger, N. .

BONE MARROW TRANSPLANTATION, 2015, 50 (02) :209-215

[5] Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years [J].

Badros, A ;

Barlogie, B ;

Siegel, E ;

Morris, C ;

Desikan, R ;

Zangari, M ;

Fassas, A ;

Anaissie, E ;

Munshi, N ;

Tricot, G .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (03) :600-607

[6]

Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x

[7] Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/Ho95 MM trial) [J].

Cavo, Michele ;

Palumbo, Antonio ;

Zweegman, Sonja ;

Dimopoulos, Meletios A. ;

Hajek, Roman ;

Pantani, Lucia ;

Beksac, Meral ;

Wester, Ruth ;

Johnsen, Hans E. ;

Mellqvist, Ulf -Henrik ;

Petrucci, Maria Teresa ;

Driessen, Christoph ;

Di Raimondo, Francesco ;

Troia, Rossella ;

Pezzi, Annalisa ;

Van der Holt, Bronno ;

Wu, Ka Lung ;

Ludwig, Heinz ;

Gay, Francesca ;

Sonneveld, Pieter .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[8] Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma [J].

Costa, Luciano J. ;

Zhang, Mei-Jie ;

Zhong, Xiaobo ;

Dispenzieri, Angela ;

Lonial, Sagar ;

Krishnan, Amrita ;

Freytes, Cesar ;

Vesole, David ;

Gale, Robert Peter ;

Anderson, Kenneth ;

Wirk, Baldeep ;

Savani, Bipin N. ;

Waller, Edmund K. ;

Schouten, Harry ;

Lazarus, Hillard ;

Meehan, Kenneth ;

Sharma, Manish ;

Kamble, Rammurti ;

Vij, Ravi ;

Kumar, Shaji ;

Nishihori, Taiga ;

Kindwall-Keller, Tamila ;

Saber, Wael ;

Hari, Parameswaran N. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (11) :1615-1624

[9] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma [J].

Dimopoulos, M. A. ;

Oriol, A. ;

Nahi, H. ;

San-Miguel, J. ;

Bahlis, N. J. ;

Usmani, S. Z. ;

Rabin, N. ;

Orlowski, R. Z. ;

Komarnicki, M. ;

Suzuki, K. ;

Plesner, T. ;

Yoon, S. -S. ;

Ben Yehuda, D. ;

Richardson, P. G. ;

Goldschmidt, H. ;

Reece, D. ;

Lisby, S. ;

Khokhar, N. Z. ;

O'Rourke, L. ;

Chiu, C. ;

Qin, X. ;

Guckert, M. ;

Ahmadi, T. ;

Moreau, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14) :1319-1331

[10] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

← 1 2 3 4 →